Evaluation of antagonistic effect of probiotics Bifidobacteria spp. on E.coli O157:H7 in vitro

Subject Areas : Applied Microbiology

Najmeh Namdar ¹ , Yahya Tahamtan ² , Mohammad Kargar ³ , Mohammad Hosein Hoseini ⁴

1 - Department of Microbiology, Jahrom Branch, Young Researcher's Clube, Islamic Azad University, Jahrom, Iran
2 - Department of Bacteriology, Razi vaccine and Serum Research Institute, Shiraz, Iran
3 - Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran
4 - Department of Bacteriology, Razi vaccine and Serum Research Institute, Shiraz, Iran

Received: 2013-08-16 Accepted : 2013-10-17 Published : 2009-10-01

Keywords: Probiotics, Bifidobacteria, E. coli O157:H7, Antagonistic Effect,

Abstract :

Background and Objectives: E. coli O157:H7 is recognized to be one of the most important food-born pathogens causing hemolytic uremic syndrome (HUS). The purpose of this study was to evaluate the effects of probiotics Bifidobacteria spp. against growth or activity of E.coli O157:H7 was used in vitro. Material and methods: This experimentally study was performed on strains isolated from clinical samples and standard E. coli O157:H7. All samples were enriched on BHI and TSA media and then, cultured on CT-SMAC. For confirmation of verotoxigenic      E. coli, biochemical, serological testes, multiplex PCR and culture on Vero cell line were performed. Also, agar gel diffusion assay was used to detect the antagonistic activity of the probiotic bacteria against pathogenic bacteria. Results: Result and discussion: According to used amount of probiotic, all the investigated strains showed a 15-30 diameter blanked area on Shiga producer E. coli O157:H7. The effect has been  repeated  in neutral pH, while organic acids had any meaningful effects on the pathogen strains. Conclusion: Probiotics are able to inhibit growth of E.coli O157:H7 and it’s not only because of organic acid or low pH but also it’s because of produce other antibacterial agents.

References:

1-Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents Enterohemorrhagic Escherichia coli O157:H7-Induced chengesin Epithelial Barrier Faunction. Infection and Immunity, 2008; 1340-1348.

2-Tarr PI, Grodon CA, Chandler WL. Shiga toxin producing Escherichia coli and hemolytic uremic syndrom. Lancet, 2005; 41:219-226.

3-Pamela HR, Davis KC, Garstka WR, Bhunia AK. Lactat dehydrogenase realase assay from vero cells to distinguish verotoxin producing Escherichia coli from non vero toxin producing strains. Journal of microbiological methods, 2000; 43:171-178.

4-Takahashi M, Taguchi H, Yamaguchi H, Osaki T. The effect of probiotic treatment with Clostridum butricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS immunology and medical microbiology, 2004; 41:219-226.

5-Momose Y, Hirayam K, Iton K. Effect of organic acids on inhibition of Escherichia coli O157:H7 colonization in gnotobiotic mice associated with infant intestinal microbiota. Antonie Leeu Wenhoek, 2008; 93:141-149.

6.Chaucheyras-Durand F, Madic J, Dondin F, Martin C. Biotic and abiotic factors influencing in vitro growth of Escherichia coli O157:H7 in ruminant digestive contents. Appled and Environmental Microbiology, 2006; 4136-4142.

7-Steven MPS, Diemen PWV, Dziva F, Jones P, Wallis T. Options for the control of enterohemorrhagic with Clostridum butricum on  enterohemorrhagic  Escherichia coli O157:H7 infection by mice. FEMS Immuonology and medical microbiology, 2004; 41:219-226.

8-Konada EY, Parken JC, Tran HT, Bryla DA, Robbins JB, Szo SC. Investigation vaccine for Escherichia, pseodomonas aeruginosa recombinant exoprotein A conjugates in adults. Jinfect Dis 1998; 177:338-387.

9-Sherman P, Soni R, Petric M, Karmali M. Surface properties of the vero cytotoxin-producing Escherichia coli O157:H7. Infection and Immunity, 1987: 1824-1829.

10- Perna NT, Plunkett G, Burland V, 25 other authors. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7.Nature, 2001; 409:529-533.

11-Dean-Nystrom EA, Bosworth BT, Moon HW. Pathogenesis of Escherichia coli O157:H7 in wean calves. Adv Exp Med Biol, 1999; 473:173-177.

12-sherman PM, Johnson-Henry KC, Yeung PH, Ngo PSC, Goulet J, Tompkins TA. Propiotic reduce Enterohemorrhagic Escherichia coli O157:H7^- and enteropathogenic Escherichia coli O127:H6-Induced chenges in polarized T84 Epithelial cell monolayers by inducing Bacterial Adhesion and cytoskeletal Rearrangements. Infection and Immunity, 2005; 5183-5188.

13-Picard C, Fioramonti J, Francois A, Robinson T, Neat F, Matuchansky C. Review article: bifidobacteria as agents-physiological effect and clinical benefits. Animal pharmacolther 2005; 22:495-512.

14-Mkcp S, Hart AL, Kamm MA, Stagg AJ, Kinght SC. Mechanism Action of probiotics: Recent Advances. Inflamm Bowel Dis. 2008;00:000-000

15-Gagnon M, Kheadr EE, Blay GL, Fliss I. In vitro inhibition of  Escherichia coli O157:H7 by bifidobacterial strains of human orgin. Food microbiology. 2004; 92:69-78.

16-Trejo FM, Minnaard J, Perez FP, DE Antoni GL. Inhibition of Closttridum difficle by Bifidobacterium supernatants. Anearobe, 2006; 12:186-193.

17-Khyani A, Mozafary N, Jandaghy Nand Ghaemi A. asare antagonisti bacterihaye lactic joda shodeh az mast bar alayhe bacteryhaye bimariza.majaleye olom pezeshki daneshgah Gorgan 1385;1:28-32  .(in persian)

18-Ogunbanwo ST, Sanni AT, Onilude AA. Characterization of bacteriocin produced by lactobacillus plantarum F1 and lactobacillus brevis OG1. African Journal of Biotechnology, 2003; 2(8)219-213.

19-Tamime A, Robinson R. Nutritional value of youghart. Jornal of Dairy Science and thecnology, 1998; 1:365-369.

20-Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by human Lactobcillus acidophilus strain LB. Appl Environ Microbiol, 1998; 64:4573-4580. 

21-Gopal PK, Prasad J, Smart J, Gill HS. In vitro adherence properties of lactobacillus rhamnosus DR20 and Bifidobacterum lactis DR10 strains and their antagonistic activity against an enterotoxigenic Eschrichia coli. Food Microbiology, 2001; 67:207-216.

22-Griffin PM, Ostoff SM, Tauxe RV, Green KD, Well JC, Lewis JH, Blake PA. Illnesses associated with Escherichia coli O157:H7 infections. abroad clinical spectrum. Ann Intern Med, 1998; 109:705-712.

23-Aldo PF, Juremi OC, Carlos ASM. The dangers of enterohaemorrhagic Escherichia coli: an emergent pathogen. Rev Biomed, 2002;13:124-129.

24-Jin LZ, Marquardt RR, Zhao X. Antagonism of Lactobacillus spp.,Streptococcus ssp.and Bifidobacteria spp.Against Enterotoxigenic Escherichia coli. Department of Animal Science.